NantKwest, Inc. (43)

Browse by Contract Category

Contracts

Promissory Note, dated February 22, 2021, issued by NantCell, Inc. (f/k/a ImmunityBio, Inc.) to Nant Capital, LLC (Filed With SEC on March 10, 2021)
ImmunityBio, Inc. (f/k/a NantKwest, Inc.) Amended Outside Director Compensation Policy (Filed With SEC on March 10, 2021)
Lease Agreement between 605 Nash, LLC and NantKwest, Inc., dated February 11, 2021 (Filed With SEC on March 4, 2021)
Supply Agreement, dated August 15, 2018, by and between ImmunityBio, Inc. and NantBio, Inc (Filed With SEC on January 19, 2021)
Exclusive License Agreement, dated February 16, 2016, by and between NantBioScience, Inc. and Etubics Corporation (Filed With SEC on January 19, 2021)
Letter Agreement, dated February 14, 2018, by and between NantPharma, LLC and Immunotherapy NANTibody, LLC (Filed With SEC on January 19, 2021)
Agreement and Plan of Merger, dated May 15, 2018, by and among ImmunityBio, Inc., Receptome Acquisition Corporation, Receptome, Inc., and the Selling Stockholder thereunder (Filed With SEC on January 19, 2021)
2015 Stock Incentive Plan of ImmunityBio, Inc., as amended, and forms of agreement thereunder (Filed With SEC on January 19, 2021)
Exclusive License Agreement, dated January 1, 2020, by and between ImmunityBio, Inc. and GlobeImmune, Inc (Filed With SEC on January 19, 2021)
Exclusive License Agreement, dated August 7, 2020, by and between ImmunityBio, Inc. and iosBio Ltd (Filed With SEC on January 19, 2021)
Assignment Agreement, dated July 31, 2017, by and between ImmunityBio, Inc. and NantOmics, LLC (Filed With SEC on January 19, 2021)
Shared Services Agreement, dated May 13, 2015, by and between ImmunityBio, Inc. and NantWorks, LLC (Filed With SEC on January 19, 2021)
Amendment #1 to Shared Services Agreement, dated January 1, 2016, by and between ImmunityBio, Inc. and NantWorks, LLC (Filed With SEC on January 19, 2021)
Assignment Agreement, dated July 2, 2017, by and between NantPharma, LLC and Immunotherapy NANTibody, LLC (Filed With SEC on January 19, 2021)
Shared Services Agreement, dated April 4, 2019, by and between ImmunityBio, Inc. and NantBio, Inc (Filed With SEC on January 19, 2021)
Sales Milestone Contingent Value Rights Agreement, dated July 31, 2017, by and between ImmunityBio, Inc. and the Stockholder Representative thereunder (Filed With SEC on January 19, 2021)
Commercial Lease, dated February 1, 2017, by and between Duley Road, LLC and Altor BioScience Manufacturing Company, LLC (Filed With SEC on January 19, 2021)
Commercial Lease, dated January 28, 2019, by and between Duley Road, LLC and ImmunityBio, Inc (Filed With SEC on January 19, 2021)
Commercial Lease, dated January 28, 2019, by and between Duley Road, LLC and ImmunityBio, Inc (Filed With SEC on January 19, 2021)
Common Stock Purchase Agreement, dated April 30, 2018, by and among ImmunityBio, Inc. and NantBio, Inc (Filed With SEC on January 19, 2021)
Offer Letter, dated August 3, 2020, by and among ImmunityBio, Inc. and David Sachs (Filed With SEC on January 19, 2021)
Common Stock Purchase Warrant, dated June 30, 2016, issued by ImmunityBio, Inc. to NantWorks, LLC (Filed With SEC on January 19, 2021)
FDA Milestone Contingent Value Rights Agreement, dated July 31, 2017, by and between ImmunityBio, Inc. and the Stockholder Representative thereunder (Filed With SEC on January 19, 2021)
Promissory Note, dated September 30, 2020, issued by ImmunityBio, Inc. to Nant Capital, LLC (Filed With SEC on January 19, 2021)
Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to NantMobile, LLC (Filed With SEC on January 19, 2021)
Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to NantCancerStemCell, LLC (Filed With SEC on January 19, 2021)
Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to NantWorks, LLC (Filed With SEC on January 19, 2021)
Amended and Restated Promissory Note, dated July 28, 2020, issued by ImmunityBio, Inc. to Nant Capital, LLC (Filed With SEC on January 19, 2021)
Agreement and Plan of Merger, dated May 19, 2017, by and among ImmunityBio, Inc., Altor Acquisition LLC, Altor BioScience Corporation and Shareholder Representative Services LLC (Filed With SEC on January 19, 2021)
Agreement and Plan of Merger, dated March 31, 2017, by and among ImmunityBio, Inc., Bio Merger Sub Inc., Liquid Genomics, Inc. and the Stockholder Representative thereunder (Filed With SEC on January 19, 2021)
Voting Agreement, dated as of December 21, 2020, by and among ImmunityBio, Inc., NantKwest, Inc., and the NantKwest, Inc. stockholders party thereto (Filed With SEC on December 22, 2020)
Agreement and Plan of Merger, dated December 21, 2020, by and among NantKwest, Inc., ImmunityBio, Inc. and Nectarine Merger Sub, Inc (Filed With SEC on December 22, 2020)
Voting Agreement, dated as of December 21, 2020, by and among NantKwest, Inc., ImmunityBio, Inc. and the ImmunityBio, Inc. stockholders party thereto (Filed With SEC on December 22, 2020)
Offer Letter between the Company and Richard Adcock, dated October 26, 2020 (Filed With SEC on November 9, 2020)
Sublease Agreement between Altor Bioscience Manufacturing Company, LLC and NantKwest, Inc., dated September 30, 2020 (Filed With SEC on November 9, 2020)
First Amendment to Facility License Agreement by and between NantWorks, LLC and NantKwest, Inc., dated September 14, 2020 (Filed With SEC on November 9, 2020)
COVID Joint Development, Manufacturing and Marketing Agreement between NantKwest, Inc. and ImmunityBio, Inc., dated August 21, 2020 (Filed With SEC on November 9, 2020)
Underwriting Agreement, dated June 24, 2020 (Filed With SEC on June 25, 2020)
First Amendment to the July 1, 2019 Letter Agreement between the Company and Immuno-Oncology Clinic, Inc., dated March 31, 2020 (Filed With SEC on May 11, 2020)
Description of the Registrants Securities (Filed With SEC on March 25, 2020)
Cost Allocation Agreement between the Company and ImmunityBio, Inc. and its subsidiaries, dated January 29, 2020 (Filed With SEC on March 25, 2020)
Letter Agreement between the Company and Immuno-Oncology Clinic, Inc., dated July 5, 2019 (Filed With SEC on August 6, 2019)
Amended and Restated 2015 Equity Incentive Plan and forms of award thereunder (Filed With SEC on June 7, 2019)